(S)-5-methyloxazolidin-2-one → (S)-3-{4-[4-(5-ethyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-5-methyloxazolidin-2-one

HRID 1804360노트

반응식

HRID 1804360 반응식
[CH2:1]([C:3]1[CH:4]=[C:5]([CH3:24])[C:6]([N:9]2[CH2:14][CH2:13][N:12]([C:15]([C:17]3[CH:22]=[CH:21][C:20](I)=[CH:19][CH:18]=3)=[O:16])[CH2:11][CH2:10]2)=[N:7][CH:8]=1)[CH3:2].[CH3:25][C@@H:26]1[O:30][C:29](=[O:31])[NH:28][CH2:27]1>>[CH2:1]([C:3]1[CH:4]=[C:5]([CH3:24])[C:6]([N:9]2[CH2:14][CH2:13][N:12]([C:15]([C:17]3[CH:22]=[CH:21][C:20]([N:28]4[CH2:27][C@H:26]([CH3:25])[O:30][C:29]4=[O:31])=[CH:19][CH:18]=3)=[O:16])[CH2:11][CH2:10]2)=[N:7][CH:8]=1)[CH3:2]

참가 물질

3

반응물 2

HCID 21794663(S)-5-methyloxazolidin-2-oneHCID 58484605[4-(5-Ethyl-3-methylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone

생성물 1

HCID 58484541(S)-3-{4-[4-(5-ethyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-5-methyloxazolidin-2-one수율 80.8%

실험 절차

By reaction and treatment in the same manner as in Example 149 and using [4-(5-ethyl-3-methylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (435 mg) described in Preparation Example 177 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (330 mg) was obtained.

후처리

  1. customBy reaction and treatment in the same manner as in Example 149
  2. customdescribed in Preparation Example 42

출처 및 근거

ORD 기록
ord-067e14e28a674da3b3c34b1fa5f01e2e
출처 데이터셋
uspto-grants-2013_01
특허 번호
US08354401B2

반응 노트

불러오는 중…